Literature DB >> 34658253

Insulin secretion and action and the response of endogenous glucose production to a lack of glucagon suppression in nondiabetic subjects.

Jon D Adams1,2, Aoife M Egan1, Marcello C Laurenti1, Daniel Schembri Wismayer1, Kent R Bailey3, Claudio Cobelli4, Chiara Dalla Man5, Adrian Vella1.   

Abstract

Type 2 diabetes is a disease characterized by impaired insulin secretion and defective glucagon suppression in the postprandial period. We examined the effect of impaired glucagon suppression on glucose concentrations and endogenous glucose production (EGP) at different degrees of insulin secretory impairment. The contribution of anthropometric characteristics, peripheral, and hepatic insulin action to this variability was also examined. To do so, we studied 54 nondiabetic subjects on two occasions in which endogenous hormone secretion was inhibited by somatostatin, with glucagon infused at a rate of 0.65 ng/kg/min, at 0 min to prevent a fall in glucagon (nonsuppressed day) or at 120 min to create a transient fall in glucagon (suppressed day). Subjects received glucose (labeled with [3-3H]-glucose) infused to mimic the systemic appearance of 50-g oral glucose. Insulin was infused to mimic a prandial insulin response in 18 subjects, another 18 received 80% of the dose, and the remaining 18 received 60%. EGP was measured using the tracer-dilution technique. Decreased prandial insulin resulted in greater % increase in peak glucose but not in integrated glucose concentrations attributable to nonsuppressed glucagon. The % change in integrated EGP was unaffected by insulin dose. Multivariate regression analysis, adjusted for age, sex, weight, and insulin dose, did not show a relationship between the EGP response to impaired suppression of glucagon and insulin action as measured at the time of screening by oral glucose tolerance. A similar analysis for hepatic insulin action also did not show a relationship with the EGP response. These data indicate that the effect of impaired glucagon suppression on EGP is independent of anthropometric characteristics and insulin action.NEW & NOTEWORTHY In prediabetes, anthropometric characteristics as well as insulin action do not alter the hepatic response to glucagon. The postprandial suppression or lack of suppression of glucagon secretion is an important factor governing postprandial glucose tolerance independent of insulin secretion.

Entities:  

Keywords:  endogenous glucose production; glucagon; hepatic insulin action; insulin action; minimal model

Mesh:

Substances:

Year:  2021        PMID: 34658253      PMCID: PMC8782666          DOI: 10.1152/ajpendo.00284.2021

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  31 in total

1.  Glucose and amino acid metabolism in mice depend mutually on glucagon and insulin receptor signaling.

Authors:  Katrine D Galsgaard; Marie Winther-Sørensen; Jens Pedersen; Sasha A S Kjeldsen; Mette M Rosenkilde; Nicolai J Wewer Albrechtsen; Jens J Holst
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-02-26       Impact factor: 4.310

2.  Impact of lack of suppression of glucagon on glucose tolerance in humans.

Authors:  P Shah; A Basu; R Basu; R Rizza
Journal:  Am J Physiol       Date:  1999-08

3.  Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients.

Authors:  P C Butler; R A Rizza
Journal:  Diabetes       Date:  1991-01       Impact factor: 9.461

4.  Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans.

Authors:  Juris J Meier; Johannes D Veldhuis; Peter C Butler
Journal:  Diabetes       Date:  2005-06       Impact factor: 9.461

5.  Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation.

Authors:  Kristine Færch; Dorte Vistisen; Giovanni Pacini; Signe S Torekov; Nanna B Johansen; Daniel R Witte; Anna Jonsson; Oluf Pedersen; Torben Hansen; Torsten Lauritzen; Marit E Jørgensen; Bo Ahrén; Jens Juul Holst
Journal:  Diabetes       Date:  2016-08-08       Impact factor: 9.461

6.  TCF7L2 Genotype and α-Cell Function in Humans Without Diabetes.

Authors:  Meera Shah; Ron T Varghese; John M Miles; Francesca Piccinini; Chiara Dalla Man; Claudio Cobelli; Kent R Bailey; Robert A Rizza; Adrian Vella
Journal:  Diabetes       Date:  2015-11-02       Impact factor: 9.461

7.  HOMA and Matsuda indices of insulin sensitivity: poor correlation with minimal model-based estimates of insulin sensitivity in longitudinal settings.

Authors:  A H Xiang; R M Watanabe; T A Buchanan
Journal:  Diabetologia       Date:  2013-12-05       Impact factor: 10.122

8.  Sympercents: symmetric percentage differences on the 100 log(e) scale simplify the presentation of log transformed data.

Authors:  T J Cole
Journal:  Stat Med       Date:  2000-11-30       Impact factor: 2.373

9.  Assessment of individual and standardized glucagon kinetics in healthy humans.

Authors:  Marcello C Laurenti; Adrian Vella; Jon D Adams; Daniel J Schembri Wismayer; Aoife M Egan; Chiara Dalla Man
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-11-02       Impact factor: 4.310

10.  Application of isotopic techniques using constant specific activity or enrichment to the study of carbohydrate metabolism.

Authors:  Adrian Vella; Robert A Rizza
Journal:  Diabetes       Date:  2009-10       Impact factor: 9.461

View more
  2 in total

1.  The relationship between insulin and glucagon concentrations in non-diabetic humans.

Authors:  Marcello C Laurenti; Praveer Arora; Chiara Dalla Man; James C Andrews; Robert A Rizza; Aleksey Matveyenko; Kent R Bailey; Claudio Cobelli; Adrian Vella
Journal:  Physiol Rep       Date:  2022-07

2.  The Effect of Diabetes-Associated Variation in TCF7L2 on Postprandial Glucose Metabolism When Glucagon and Insulin Concentrations Are Matched.

Authors:  Jon D Adams; Aoife M Egan; Marcello C Laurenti; Daniel Schembri Wismayer; Kent R Bailey; Claudio Cobelli; Chiara Dalla Man; Adrian Vella
Journal:  Metab Syndr Relat Disord       Date:  2022-04-18       Impact factor: 2.363

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.